Voyager Therapeutics (NASDAQ:VYGR) Raised to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q3 2024 earnings at ($0.08) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.41) […]

Leave a Reply

Your email address will not be published.

Previous post Letters to the editor
Next post Match Group, Inc. (NASDAQ:MTCH) Receives $42.34 Average PT from Analysts